Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.
Phase 3positiveZenkudatabirafusp-tedPositive
AI Analysis
Summary
Zenkuda (tarcocimab tedromer) met the primary endpoint in the pivotal DAYBREAK Phase 3 trial for wet age-related macular degeneration, demonstrating meaningful vision gains and sustained retinal drying with 54% of patients on 6-month dosing intervals.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met primary endpoint (p-value of 0.0007) demonstrating meaningful vision gains and rapid sustained retinal drying with 54% of patients on 6-month dosing interval
Importance:8/10
Sentiment:
0.95
Phase 3 dataPrimary endpoint metwAMDVision gainsExtended dosing interval
Read the original article
Published by PR Newswire Biotech on September 28, 2026 10:30 AM